...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Avoid The Bag - Blog post preview....

Led, 

Good start. I think you can add depth to this by discussing a bit about RVX-208 being an orally available  bromodomain 2 selective BET inhibitor. Talk up that it is the only selective BET inhibitor in clinical trials, that all others hit both bromodomains and thus far are limited to oncology indications and no further than Phase 2. Also touch on apoAI/HDL, atherosclerosis, plaque reduction, inflammation, complement, etc. Don't just embed the video as a way to educate about mechanism of RVX-208, but add text in your article too. 

BearDownAZ 

Share
New Message
Please login to post a reply